That gap is not a knowledge problem. It is a measurement and design problem. Understanding why it persists, and what it costs, is the first step toward building prevention infrastructure that measures what actually matters.
The evidence is not the problem
In 2002, a landmark study published in the New England Journal of Medicine examined 6,213 men referred for clinical exercise testing. The findings were striking: peak exercise capacity, measured in metabolic equivalents, was the strongest predictor of all-cause mortality among both healthy individuals and those with cardiovascular disease.
Every one-MET increase in exercise capacity was associated with a 12 percent improvement in survival. Exercise capacity outperformed hypertension, diabetes, smoking history, and cholesterol as a prognostic variable.
The clinical implication is difficult to ignore. Functional capacity is not a lifestyle detail. It is one of the most powerful signals of cardiovascular risk that clinicians can measure. The evidence is not the bottleneck. The system is.
What is trying, and where it falls short
One of the most important attempts to close this gap has been the Exercise is Medicine initiative, launched in 2007 by the American College of Sports Medicine and the American Medical Association. It established a critical premise: physical activity should be assessed and managed as a clinical vital sign at every point of care.
That contribution matters. Exercise is Medicine helped create a shared vocabulary, aligned professional organizations, and pushed exercise assessment into clinical conversations in a way that had not existed before.
Asking patients about activity is not the same as managing functional capacity over time.
Exercise is Medicine identified the problem correctly and created the momentum. The infrastructure to move from a screened answer to a longitudinal, dose-appropriate, clinically tracked intervention is still underdeveloped.
The proof of concept, and why it does not scale
If Exercise is Medicine represents the aspiration, structured cardiac rehabilitation represents the proof of concept: what clinical exercise looks like when properly resourced.
The outcomes are well established. Cardiac rehabilitation improves functional capacity, reduces rehospitalization risk, and is associated with improved survival among patients recovering from major cardiac events.
It also reaches only a fraction of the patients who could benefit. In Ontario, cardiac rehabilitation programs have historically served fewer than 30 percent of eligible post-hospitalized cardiac patients, with participation even lower among older and lower-income populations.
This is not a regional anomaly. It is a structural feature of how healthcare has designed, funded, and measured clinical exercise intervention.
The nuance most platforms miss
Digital health platforms have expanded access to activity monitoring: heart-rate data, step counts, workout logging, and app-based prompts. But access to activity data is not the same as clinical management of functional capacity.
The key concepts are exercise dose and trajectory. Exercise dose is the physiologically appropriate stimulus required to produce meaningful adaptation based on baseline capacity, clinical risk, and rate of response. Trajectory is whether that capacity is actually improving, stagnating, or declining over time.
Two patients may both be told to exercise more. One is rebuilding cardiovascular function after a heart attack. The other is trying to reduce long-term cardiometabolic risk before an event occurs. The recommendation may sound the same. The appropriate intensity, pace of progression, monitoring needs, and clinical interpretation are not.
This is the gap that neither general wellness platforms nor traditional programs fully occupy: the space between exercise advice and exercise infrastructure, between a recommendation and a managed clinical behavior.
What closing the gap requires
Making exercise clinically meaningful requires capabilities that current healthcare still lacks at scale.
- Validated baseline measurement. Functional capacity must be assessed at intake using measures with clinical meaning, such as peak VO2 estimation, MET-level assessment, or validated tools such as the Duke Activity Status Index.
- Longitudinal tracking of the metric that predicts outcomes. Step counts and attendance are process measures. Functional capacity change is closer to the outcome healthcare should care about.
- Equity-sensitive delivery. Prevention infrastructure that cannot reach socioeconomically disadvantaged patients will miss many of the patients with the most to gain.
- Reimbursement models aligned with functional outcomes. When payers rely on participation metrics alone, programs are incentivized to report who showed up rather than who improved.
None of these requirements are technologically or scientifically impossible. They are operationally underdeveloped.
Why this moment matters
Two converging forces are creating an unusual window for progress. First, the rise of GLP-1 receptor agonists is reshaping cardiometabolic prevention. These medications can produce substantial weight loss, but without structured resistance and aerobic exercise, some of that loss may include lean mass. Managing risk well requires attention not only to weight, but to functional reserve.
Second, value-based care is expanding across Medicare Advantage, accountable care organizations, and employer-sponsored health plans. These models create stronger incentives to pay for measurable outcomes rather than isolated encounters.
The missing piece is not the evidence or the technology. It is the clinical architecture that connects the two, making functional capacity visible, interpretable, and accountable within the care system.
Frequently asked questions
Why has Exercise is Medicine not solved the problem of clinical exercise delivery?
Exercise is Medicine successfully established exercise as a clinical vital sign and helped move physical activity into the clinical conversation. The gap it did not close is the infrastructure between assessment and management.
What is exercise dose, and why does it matter in cardiovascular prevention?
Exercise dose refers to the intensity, frequency, duration, and progression required to produce meaningful cardiovascular adaptation for a specific patient. Baseline capacity and response over time determine what the clinical intervention should actually be.
Why are participation metrics not enough for prevention programs?
Participation metrics show whether someone attended, logged in, or completed a program. They do not show whether functional capacity improved or cardiovascular risk meaningfully changed.
Why do lower-income patients have worse outcomes after a heart attack even when they receive care?
Research following Ontario heart attack survivors found that differences in functional recovery helped explain long-term survival differences across income groups.
What metric should cardiovascular prevention programs use instead of participation rates?
Cardiovascular prevention programs should track functional capacity, such as peak VO2 or MET-equivalent measures, where feasible. These measures are more closely linked to survival and clinical risk than attendance or completion rates alone.
How does the rise of GLP-1 medications change the case for clinical exercise infrastructure?
GLP-1 medications are changing cardiometabolic care, but long-term prevention still depends on preserving and improving functional capacity. Exercise infrastructure is needed to assess baseline capacity, dose exercise appropriately, and track whether patients are gaining cardiovascular reserve.
References
- Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med. 2002;346(11):793-801.
- Alter DA, Franklin B, Ko DT, Austin PC, Lee DS, et al. Socioeconomic status, functional recovery, and long-term mortality among patients surviving acute myocardial infarction. PLoS ONE. 2013;8(6):e65130.
- Kraus WE, Powell KE, Haskell WL, et al. Physical activity, all-cause and cardiovascular mortality, and cardiovascular disease. Med Sci Sports Exerc. 2019;51(6):1270-1281.
- Candido E, Richards JA, Oh P, et al. The relationship between need and capacity for multidisciplinary cardiovascular risk-reduction programs in Ontario. Can J Cardiol. 2011;27(2):200-207.
- Levine S, Malone E, Lekiachvili A, Briss P. Health care industry insights: why the use of preventive services is still low. Prev Chronic Dis. 2019;16:E180625.